Virios Therapeutics, Inc.

Equities

VIRI

US92829J1043

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.4695 ^USD	+3.01%		+7.81%	-18.35%

Feb. 29	Virios Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
Jan. 22	Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid	CI

Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid

January 22, 2024 at 09:00 am EST

Virios Therapeutics, Inc. announced plans for advancing IMC-2 (combination of valacyclovir and celecoxib) as a treatment for the fatigue, orthostatic intolerance and other symptoms associated with LC, also known as post-acute sequelae of SARS-CoV-2 infection (?PASC?). The Company is targeting the initiation of a Phase 2 program in the second half of 2024, with data expected in 2025.

Latest news about Virios Therapeutics, Inc.

Virios Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid	Jan. 22	CI
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID	Jan. 02	CI
Virios Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Transcript : Virios Therapeutics, Inc., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Virios Therapeutics, Inc. Announces Termination of At-The-Market Sales Agreement	23-09-18	CI
Virios Therapeutics Shares Slump After Company Reports Q2 Loss	23-08-10	MT
Transcript : Virios Therapeutics, Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Virios Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Virios Therapeutics, Inc. Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as A New Treatment Option for Fibromyalgia	23-08-09	CI
Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-Covid Symptoms Following Treatment with A Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study	23-07-17	CI
Virios Therapeutics, Inc.(NasdaqCM:VIRI) dropped from Russell 3000E Index	23-06-23	CI
Virios Therapeutics, Inc.(NasdaqCM:VIRI) dropped from Russell Microcap Index	23-06-23	CI
Virios Therapeutics, Inc.(NasdaqCM:VIRI) dropped from Russell Microcap Growth Index	23-06-23	CI
Virios Therapeutics, Inc.(NasdaqCM:VIRI) dropped from Russell 3000E Growth Index	23-06-23	CI
Transcript : Virios Therapeutics, Inc. - Shareholder/Analyst Call	23-06-15
Virios Therapeutics Regains Compliance With Nasdaq Listing Rule	23-05-26	MT
Virios Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Virios Therapeutics Shares Rise 52% After FDA Feedback for IMC-1	23-04-25	DJ
Certain Common Stock of Virios Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAR-2023.	23-03-18	CI
Certain Warrants of Virios Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAR-2023.	23-03-18	CI
Certain Options of Virios Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAR-2023.	23-03-18	CI
Virios Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
Virios Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023	23-02-13	CI

Chart Virios Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Virios Therapeutics, Inc. is a development-stage biotechnology company. The Company is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (FM) and Long-COVID (LC). Its lead candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination, dual mechanism antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden. IMC-2 is a combination of valacyclovir and celecoxib that is believed to have specific activity against Epstein-Barr virus (herpesvirus HHV-4), as well as other herpesviruses. IMC-1 and IMC-2 combine two specific mechanisms of action purposely designed to inhibit herpesvirus activation and replication, thereby converting activated herpesvirus back to dormancy and/or by keeping the herpesvirus in a latent or dormant state.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.4695 USD

Average target price

2.2 USD

Spread / Average Target

+368.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VIRIOS THERAPEUTICS, INC.	-18.35%	9.04M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs